Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Smallpox Vaccine”

70 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 70 results

Early research (Phase 1)Study completedNCT05762523
What this trial is testing

Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years

Who this might be right for
SmallpoxMonkeypoxCowpox+1 more
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" 60
Large-scale testing (Phase 3)Study completedNCT01913353
What this trial is testing

A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®

Who this might be right for
18-42 Year Old Healthy Vaccinia-naïve Subjects
Bavarian Nordic 440
Testing effectiveness (Phase 2)Looking for participantsNCT07379580
What this trial is testing

Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa

Who this might be right for
Mpox (Monkeypox)SmallpoxOrthopoxvirus Infection
BioNTech SE 310
Early research (Phase 1)Study completedNCT00079820
What this trial is testing

Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults

Who this might be right for
Smallpox
Sanofi Pasteur, a Sanofi Company 110
Early research (Phase 1)Study completedNCT00001043
What this trial is testing

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

Who this might be right for
HIV InfectionsHIV Seronegativity
National Institute of Allergy and Infectious Diseases (NIAID) 20
Early research (Phase 1)Study completedNCT00002261
What this trial is testing

A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers

Who this might be right for
HIV Infections
Bristol-Myers Squibb
Testing effectiveness (Phase 2)Study completedNCT00081835
What this trial is testing

Evaluation and Treatment of Eye Complications of Vaccinia Vaccination

Who this might be right for
Vaccinia
National Eye Institute (NEI) 400
Large-scale testing (Phase 3)Study completedNCT05846243
What this trial is testing

Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years

Who this might be right for
SmallpoxMonkeypoxCowpox+1 more
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" 334
Large-scale testing (Phase 3)Study completedNCT01056770
What this trial is testing

Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers

Who this might be right for
Smallpox
Seoul National University Hospital 88
Not applicableStudy completedNCT00928577
What this trial is testing

Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)

Who this might be right for
Smallpox
Emergent BioSolutions 14,108
Not applicableStudy completedNCT01540929
What this trial is testing

Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel

Who this might be right for
Smallpox
Emergent BioSolutions 5,001
Large-scale testing (Phase 3)Active Not RecruitingNCT06844500
What this trial is testing

Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC

Who this might be right for
NeonateMaternal TransmissionMpox+5 more
Jean-Pierre Van geertruyden 359
Testing effectiveness (Phase 2)Study completedNCT00879762
What this trial is testing

High Dose IMVAMUNE® in Vaccinia-Naive Individuals

Who this might be right for
Smallpox
National Institute of Allergy and Infectious Diseases (NIAID) 91
Early research (Phase 1)Study completedNCT00189969
What this trial is testing

Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects

Who this might be right for
Smallpox
Bavarian Nordic 50
Testing effectiveness (Phase 2)Study completedNCT00316524
What this trial is testing

A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects

Who this might be right for
Smallpox
Bavarian Nordic 745
Testing effectiveness (Phase 2)Study completedNCT00053482
What this trial is testing

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

Who this might be right for
Smallpox
Emergent BioSolutions 357
Early research (Phase 1)Study completedNCT00053742
What this trial is testing

Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox

Who this might be right for
Healthy
National Institute of Allergy and Infectious Diseases (NIAID) 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT06549530
What this trial is testing

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

Who this might be right for
Monkeypox (Mpox)
Bavarian Nordic 460
Testing effectiveness (Phase 2)Study completedNCT05995275
What this trial is testing

Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age

Who this might be right for
SmallpoxMpox
ModernaTX, Inc. 351
Testing effectiveness (Phase 2)Study completedNCT00857493
What this trial is testing

Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

Who this might be right for
Smallpox
Bavarian Nordic 120
Load More Results